HCOs

Views & Analysis

On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.